CELL AND GENE THERAPY
Ultima Genomics | June 09, 2022
Olink Holding AB (publ) ("Olink") (Nasdaq: OLK) and Ultima Genomics ("Ultima") today announced that they have entered into a collaboration to enable the use of the Olink® Explore high-throughput proteomics platform with Ultima's sequencing architecture.
Ultima Genomics and Olink are working towards a seamless pairing of the existing Olink® Explore assay and Ultima Genomics' sequencing system, and are collaborating with joint customers to enable larger-scale projects. The companies expect this will be accomplished by offering Ultima-specific library modules, along with an Olink-provided data analysis solution. Initial proof of concept data gathered by the companies shows similar performance to the existing Explore assay, signaling its potential for high-throughput proteomics customers. Additional information will be provided by Ultima during a panel discussion today, June 8, at the Advances in Genome Biology and Technology (AGBT) general meeting in Orlando, Florida.
With the next-generation sequencing market expected to undergo a significant evolution in the months and years ahead, Olink is committed to enabling broad access to its unique and industry-leading Explore technology, As more labs embrace the promise of proteomics, we believe we are approaching an inflection point; and efforts such as our collaboration with Ultima will be a critical factor in developing the market and reaching as many customers as possible."
Jon Heimer, CEO of Olink.
This non-exclusive collaborative framework is a continuation of Olink's strategy it has executed in NGS since 2020 and combines the strengths of both companies' technologies. These efforts are in line with Olink's previously communicated operational planning and are intended to provide customers with options in choosing the sequencing platform that is optimal for their needs.
Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st-century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America, and Asia. Olink is headquartered in Uppsala, Sweden.
About Ultima Genomics
Ultima Genomics is unleashing the power of genomics at scale. The Company's mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology's complexity and dynamic change—and a further need to challenge conventional next-generation sequencing technologies. Ultima's revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth, and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information and catalyze the next phase of genomics in the 21st century.
Bio Detection K9 | May 19, 2022
Bio Detection K9 (BDK9) is pleased to announce its upcoming detection service for Leafroll and Red Blotch Virus in grapes. Of the 86 different viruses known to infect vineyards, Leafroll 3 and Red Blotch virus are among the most prevalent. These pathogens can infect all wine, table and rootstock grapes. They occur in grape production areas around the world and are responsible for causing over 70 billion dollars of damage in the United States alone.
To combat these insidious diseases, BDK9 is launching a cost-effective service that can quickly and accurately pinpoint infected vines before the pathogens have a chance to spread. Utilizing proprietary technology, BDK9 develops training aids that have the scent of the target viruses. The result is a harmless substance with a highly specific scent that dogs are systematically trained to detect. This is the same proven methodology BDK9 employs to screen humans for COVID-19 at airports, stadiums and public events worldwide.
The challenge is like finding a needle in a haystack when trying to detect an infected plant among thousands of potentially threatened vines, But thanks to our completely safe training aid, we can teach canines to accurately detect a viral disease in any tissue, roots, vines, or leaves."
Dr. William Schneider, Chief Research Scientist for BDK9.
BDK9's unique technology is effective in many different areas, from humans to agriculture, and the company is proud to be at the forefront of disease detection.
We're thrilled about the release of this new, cutting-edge technology and are pleased to offer this to the wine industry, Our company continues to set the standard in agriculture disease detection with our effective programs, and we take great pride in the fact that we're able to take action and truly address these important issues as they arise. "
Wade Morrell, CEO of BDK9.
About Bio Detection K9
Bio Detection K9 (BDK9) is the world leader in precision agriculture and human host pathogen bio detection. Led by a veteran USDA virologist, BDK9 works with canines and cutting-edge technology to identify disease in both humans and agriculture. Their dogs are trained to isolate individual pathogens with unparalleled accuracy and specificity. All training is performed safely and Bio Detection Canines™ are unharmed during the process. BDK9 is not only at the forefront of precision pathogen detection through this unique combination of technology and training, but their services are efficient, cost effective and non-invasive.
DxTerity | June 13, 2022
DxTerity Diagnostics today announced the commercial launch of their IFN-1 Test for patients with Systemic Lupus Erythematosus (SLE or lupus). The IFN-1 Test supports the advancement of precision medicine to improve the lives of patients living with lupus.
DxTerity's test measures a key biomarker, Type-1 Interferon (IFN-1), an important indicator of SLE disease severity and prognosis. High IFN-1 levels have been shown to lead to higher likelihood of disease severity and an increased risk for the development of lupus nephritis in SLE patients. The DxTerity IFN-1 Test is the first commercial IFN-1 gene expression assay.
Patients living with lupus can find it difficult to predict and interpret symptoms. Each person's experience is unique and not all patients respond to standard treatments. Disease symptoms and treatment failure may be the result of a person's specific genomic activity. The DxTerity IFN-1 Test measures the expression levels of 4 genes associated with IFN-1 activity and identifies a patient as IFN-1 high or low. This information can be used by a healthcare provider to guide treatment.
Rheumatologists have long been faced with limited therapy options for lupus management. With the recent FDA approval and availability of the Type-1 Interferon receptor blocking therapy anifrolumab (Saphnelo®), lupus patients have a new and much needed treatment option.
We are excited to launch the DxTerity IFN-1 Test, the first available IFN-1 gene signature test to provide information regarding a person's unique genomic activity, It is our mission to transform patient care by developing diagnostic tools that support a personalized approach to the treatment of immune-mediated disease."
Bob Terbrueggen, Ph.D., Founder and CEO of DxTerity Diagnostics.
DxTerity Diagnostics is an ISO 13485-certified genomics company with a CLIA-licensed, CAP-accredited laboratory based near Los Angeles, CA. DxTerity Diagnostics develops simple, fast, and affordable genomic tests for disease diagnosis and disease monitoring.